ReviewTransgenic research2007
Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals.
Review in Transgenic research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines.Plants (Basel, Switzerland) · 2021Review
- Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants.Retrovirology · 2021Article
- Process Simulation and Techno-Economic Analysis of Large-Scale Bioproduction of Sweet Protein Thaumatin II.Foods (Basel, Switzerland) · 2021Article
- Potential Applications of Plant Biotechnology against SARS-CoV-2.Trends in plant science · 2020Review
- Novel Bioengineered Cassava Expressing an Archaeal Starch Degradation System and a Bacterial ADP-Glucose Pyrophosphorylase for Starch Self-Digestibility and Yield Increase.Frontiers in plant science · 2018Article
- Evaluation of plant-producedThe Onderstepoort journal of veterinary research · 2017Article
- Recombinant biologic products versus nutraceuticals from plants - a regulatory choice?British journal of clinical pharmacology · 2017Review
- Assessing the bioconfinement potential of a Nicotiana hybrid platform for use in plant molecular farming applications.BMC biotechnology · 2013Article
- High-level production of human interleukin-10 fusions in tobacco cell suspension cultures.Plant biotechnology journal · 2013Article
- Improving pharmaceutical protein production in Oryza sativa.International journal of molecular sciences · 2013Review
- Recombinant monoclonal antibody yield in transgenic tobacco plants is affected by the wounding response via an ethylene dependent mechanism.Transgenic research · 2012Article
- Feasibility of Pisum sativum as an expression system for pharmaceuticals.Transgenic research · 2012Review
- Multiple recent horizontal transfers of the cox1 intron in Solanaceae and extended co-conversion of flanking exons.BMC evolutionary biology · 2011Article
- Genetic engineering of radish: current achievements and future goals.Plant cell reports · 2011Review
- Gene transfer into Solanum tuberosum via Rhizobium spp.Transgenic research · 2011Article
- Molecular Pharming: future targets and aspirations.Human vaccines · 2011Review
- Evolution of plant-made pharmaceuticals.International journal of molecular sciences · 2011Review
- Recombinant cytokines from plants.International journal of molecular sciences · 2011Review
- Optimisation of contained Nicotiana tabacum cultivation for the production of recombinant protein pharmaceuticals.Transgenic research · 2010Article
- Higher accumulation of F1-V fusion recombinant protein in plants after induction of protein body formation.Plant molecular biology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Significant advances over the last few years have seen plant-made pharmaceuticals (PMPs) move from the exploratory research phase towards clinical trials, with the first commercial products for human use expected to reach the market by 2009. Europe has yet to witness the commercial application of PMP technology, although at least one product has begun phase II clinical trials with others following close behind. These emerging products are set to challenge the complex and overlapping regulations that currently govern GM plants and 'conventional' pharmaceutical production. The areas of responsibility are being mapped out between the different EU regulatory agencies, with specific guidelines currently being drawn up for the regulation of PMPs. This article discusses issues surrounding the development of robust risk-assessment and risk-management practices based on health and environmental impact, while working with EU regulatory authorities to ensure appropriate regulatory oversight.
Indexed as
Identifiers
17285266What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.